Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer
![](/xmlui/themes/Mirage2//images/mime.png)
Erişim
info:eu-repo/semantics/closedAccessTarih
2021Yazar
Kefeli, UmutArslan, Çağatay
Yıldırım, Mahmut Emre
Işıkdoğan, Abdurrahman
Karadurmuş, Nuri
Karabulut, Bülent
Çubukçu, Erdem
Çiçin, İrfan
Yalçın, Şuayib
Türk, Hacı Mehmet
Bilir, Cemil
Karaca, Mustafa
Artaç, Mehmet
Şendur, Mehmet Nahit
Alacacıoğlu, Ahmet
Tanrıkulu Şimşek, Eda
Dane, Faysal
Bilici, Ahmet
Çevik, Duygu
Gümüş, Mahmut
Üst veri
Tüm öğe kaydını gösterKünye
Kefeli, U., Arslan, Ç., Yıldırım, M. E., Işıkdoğan, A., Karadurmuş, N., Karabulut, B. ... Gümüş, M. (2021). Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer. Journal of Clinical Oncology. https://dx.doi.org/10.1200/JCO.2021.39.15_suppl.e15561Özet
Background: Efficacy of anti-angiogenic and anti-EGFR agents has been demonstrated metastatic colorectal cancer (mCRC). Real-world evidence is especially important to detect the findings of patients outside of clinical trials. It complements together with clinical trials. However, there are a few studies that evaluated these treatments with biologics in the real-world setting. Recognizing the change that has occurred over the years will also shed light on future approaches. Therefore, we aimed to investigate the real-world data of patients with RAS-wild type mCRC. Methods: Medical records from 28 centers were collected for patients diagnosed with RAS wild-type mCRC between January 2016 and April 2019 and were included into the study. Histopathological, molecular and clinical characteristics of the patients were recorded. The treatment duration, response rate, progression-free survival and safety results were determined. Also, changes over the years were compared. Patients were compared according to the first-line biological treatments as anti-EGFR group (Group A and B) (panitumumab and cetuximab) and anti-VEGF group (group C).
WoS Q Kategorisi
Q1Kaynak
Journal of Clinical OncologyCilt
39Sayı
15Bağlantı
https://dx.doi.org/10.1200/JCO.2021.39.15_suppl.e15561https://hdl.handle.net/20.500.12511/8619
Koleksiyonlar
- Bildiri Koleksiyonu [516]
- WoS İndeksli Yayınlar Koleksiyonu [6696]